Peggy Amoakohene, MD
Internal Medicine · Charlottesville, VANPI 1346635307
Payments from drug & device makers
Across 65 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$260
- Novo Nordisk$138
- Abbott$115
- Averitas Pharma Inc.$101
- Sanofi$99
- Insulet Corporation$92
- plus $637 from 17 others
What the payments were for
- Food & beverage$1,443100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $260 |
| Novo Nordisk | 7 | $138 |
| Abbott | 5 | $115 |
| Averitas Pharma Inc. | 5 | $101 |
| Sanofi | 1 | $99 |
| Insulet Corporation | 4 | $92 |
| Sanofi-aventis U.S. LLC | 4 | $85 |
| IBSA Pharma Inc. | 3 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Boehringer Ingelheim | 2 | $51 |
| Lifescan, Inc. | 2 | $48 |
| Amneal Pharmaceuticals LLC | 2 | $45 |
| Amgen | 2 | $40 |
| Medtronic | 2 | $33 |
| Bayer | 2 | $29 |
| Radius Health, Inc. | 1 | $26 |
| Tolmar, Inc. | 1 | $25 |
| Novartis | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| Cardinal Health 414 LLC | 1 | $22 |
| Merck | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Boston Scientific | 1 | $16 |
How this compares
$1,443 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $266,371 |
| JardianceEmpagliflozin | 130 | $203,736 |
| TrulicityDulaglutide | 82 | $137,205 |
| MounjaroTirzepatide | 82 | $136,650 |
| JanuviaSitagliptin Phosphate | 54 | $49,125 |
| FarxigaDapagliflozin Propanediol | 25 | $37,427 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $32,789 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $25,827 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $24,722 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $17,776 |
| Novolog FlexpenInsulin Aspart | 41 | $16,006 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $11,850 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $10,659 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $8,628 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 86 | $7,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $260 | $276,486196 claims |
| Novo NordiskOzempic, Novolog | $138 | $267,687138 claims |
| Boehringer IngelheimJardiance | $51 | $203,736130 claims |
| MerckJanuvia | $22 | $49,12554 claims |
| Sanofi-aventis U.S. LLCLantus | $85 | $4,20316 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $2,759173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Charlottesville
- James ClarkCharlottesville$16.2M
- Michael DevittCharlottesville$3.5M
- Sue BrownCharlottesville$2.4M
- Jeffrey SturekCharlottesville$156K
- Leroy VaughanRichmond$20.8M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.